Pfizer's CD33-positive AML drug Mylotarg approved in Europe

Pfizer Inc. (NYSE:PFE) said the European Commission approved Mylotarg gemtuzumab ozogamicin for treatment-naïve, de novo, CD33-positive acute myelogenous leukemia in patients ages 15 and older. The pharma said the drug is the only AML therapy approved in Europe that targets CD33.

In February, EMA’s CHMP recommended approval of Mylotarg in the indication (see BioCentury, March 1)...